South Korean (KOSPI) Personal Products Industry Analysis

Industry Valuation and Performance

Has the South Korean Personal Products Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 31 May 2026	₩41.5t	₩30.3t	₩1.2t	13x	34.3x	1.4x
Tue, 28 Apr 2026	₩49.1t	₩29.5t	₩1.0t	20.6x	48x	1.7x
Thu, 26 Mar 2026	₩41.0t	₩29.4t	₩1.1t	17.6x	38.3x	1.4x
Sat, 21 Feb 2026	₩42.4t	₩29.0t	₩867.0b	21.1x	48.9x	1.5x
Mon, 19 Jan 2026	₩35.4t	₩29.0t	₩867.0b	19.4x	40.8x	1.2x
Wed, 17 Dec 2025	₩36.9t	₩29.0t	₩867.0b	19.9x	42.5x	1.3x
Fri, 14 Nov 2025	₩35.4t	₩28.5t	₩803.9b	21.2x	44.1x	1.2x
Sun, 12 Oct 2025	₩37.8t	₩28.6t	₩808.2b	21.9x	46.8x	1.3x
Tue, 09 Sep 2025	₩37.2t	₩28.6t	₩825.0b	22.6x	45.1x	1.3x
Thu, 07 Aug 2025	₩39.7t	₩28.2t	₩1.5t	18.6x	26x	1.4x
Sat, 05 Jul 2025	₩36.6t	₩28.1t	₩1.5t	18.9x	24x	1.3x
Mon, 02 Jun 2025	₩34.1t	₩27.8t	₩1.5t	18x	22.9x	1.2x
Wed, 30 Apr 2025	₩28.9t	₩27.2t	₩1.6t	14.9x	18.4x	1.1x
Fri, 28 Mar 2025	₩26.7t	₩27.2t	₩1.5t	15.7x	17.5x	1x
Sun, 23 Feb 2025	₩27.0t	₩26.6t	₩1.4t	18.5x	19.5x	1x
Tue, 21 Jan 2025	₩26.7t	₩26.6t	₩1.4t	18.2x	19.3x	1x
Thu, 19 Dec 2024	₩26.0t	₩8.9t	₩417.2b	18.2x	62.3x	2.9x
Sat, 16 Nov 2024	₩25.3t	₩26.2t	₩1.4t	17.5x	18.1x	1x
Mon, 14 Oct 2024	₩29.2t	₩26.2t	₩1.4t	20.4x	21x	1.1x
Wed, 11 Sep 2024	₩30.5t	₩26.2t	₩1.4t	20.4x	21.9x	1.2x
Fri, 09 Aug 2024	₩28.5t	₩26.0t	₩688.7b	22.7x	41.4x	1.1x
Sun, 07 Jul 2024	₩32.5t	₩26.0t	₩688.7b	26.1x	47.2x	1.3x
Tue, 04 Jun 2024	₩37.0t	₩26.0t	₩670.8b	26.4x	55.2x	1.4x
Thu, 02 May 2024	₩32.9t	₩25.5t	₩640.7b	25.3x	51.3x	1.3x
Sat, 30 Mar 2024	₩27.4t	₩25.5t	₩604.1b	23.8x	45.3x	1.1x
Mon, 26 Feb 2024	₩25.2t	₩25.4t	₩272.7b	33.2x	92.3x	1x
Wed, 24 Jan 2024	₩26.3t	₩25.5t	₩219.3b	33.2x	120.1x	1x
Fri, 22 Dec 2023	₩26.1t	₩25.2t	₩205.6b	31.4x	126.9x	1x
Sun, 19 Nov 2023	₩25.7t	₩25.0t	₩222.8b	29.7x	115.4x	1x
Tue, 17 Oct 2023	₩25.2t	₩25.1t	₩238.2b	24.7x	105.9x	1x
Thu, 14 Sep 2023	₩27.8t	₩25.1t	₩238.2b	27.4x	116.7x	1.1x
Sat, 12 Aug 2023	₩29.2t	₩24.8t	₩228.1b	35.1x	128.1x	1.2x
Mon, 10 Jul 2023	₩23.8t	₩24.8t	₩225.0b	33.6x	105.6x	1x
Wed, 07 Jun 2023	₩25.8t	₩24.7t	₩219.2b	26.9x	117.9x	1x

Current Industry PE

Investors are pessimistic on the South Korean Personal Products industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 34.3x which is lower than its 3-year average PE of 54.8x.

The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.4x.

Past Earnings Growth

The earnings for companies in the Personal Products industry have grown 77% per year over the last three years.
Revenues for these companies have grown 7.1% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the South Korean Consumer Staples industry?


KR Market	6.68%
Consumer Staples	-4.61%
Personal Products	-4.18%
Personal Products	-4.18%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
A278470 APR	₩395.50k	1.2% +₩168.5b	243.0%	PE41.5x
A123330 Genic	₩22.75k	16.4% +₩25.0b	-37.8%	PE9.4x
A257990 Nowcos	₩8.30k	3.6% +₩1.7b	43.6%	n/a
A289170 Bioten	₩3.30k	13.4% +₩1.4b	-15.1%	n/a
A178600 Daedong Korea Ginseng	₩2.09k	7.7% +₩667.4m	-8.5%	n/a

Hyundai Bioscience Discloses XAFTY IC50 Data for Ebola

Hyundai Bioscience announced on May 20th that XAFTY has a strong likelihood of being able to treat Ebola and Hantavirus given its low IC50 (50% inhibitory concentration) for those viruses. The IC50 data is the drug concentration that can inhibit viral replication by 50%. The lower the value, the stronger the antiviral effect with a smaller amount. XAFTY has as IC50 level of 0.28 µM against SARS-CoV-2, the pathogen in COVID-19, and has already proven its therapeutic efficacy in human COVID-19 clinical trials. The IC50 level of XAFTY is even lower for the Ebola virus at 0.125 µM. This suggests that XAFTY could be a promising agent to treat Ebola-infected patients. XAFTY proved its safety through the COVID-19 Phase 2/3 clinical trials and an ongoing Dengue Phase 2/3 clinical trial in Vietnam. No severe adverse events have been reported so far across all dosage groups, reaffirming its clinical safety. Hyundai Bioscience reports that it has enough drug inventory for immediate supply to the outbreak frontlines. XAFTY® has reported on its broad antiviral activity. It demonstrated exceptional inhibitory efficacy of less than 0.125 µM against the Severe Fever with Thrombocytopenia Syndrome (SFTS) virus, which serves as scientific evidence for activity against Hantavirus. Both SFTS virus and Hantavirus belong to the same virus class.

South Korean (KOSPI) Personal Products Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Investor sentiment improves as stock rises 16%

Hyundai Bioscience Discloses XAFTY IC50 Data for Ebola

Solid Earnings May Not Tell The Whole Story For d'Alba Global (KRX:483650)

Additional Considerations Required While Assessing Kolmar Korea's (KRX:161890) Strong Earnings

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Earnings quality

First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 15%

Now 23% overvalued

AMOREPACIFIC Holdings Corp. to Report Q1, 2026 Results on Apr 29, 2026

Daedong Korea Ginseng Co., Ltd. announced that it expects to receive KRW 3 billion in funding

Bioten Co., Ltd., Annual General Meeting, Mar 31, 2026

Nowcos Co., Ltd, Annual General Meeting, Mar 30, 2026